12BEntitlement to botulinum toxin pharmaceutical benefits for treatment of chronic migraine

12B Entitlement to botulinum toxin pharmaceutical benefits for treatment of chronic migraine

(1) This section applies to eligible patients receiving treatment for chronic migraine who: (a) are aged 18 years or more, and (b) have experienced an average of 15 or more headache days per month, with at least 8 days of migraine, over a period of at least 6 months, prior to commencement of treatment with a botulinum toxin pharmaceutical benefit, and (c) have experienced an inadequate response, intolerance or a contraindication to at least three prophylactic migraine medications prior to commencement of treatment with a botulinum toxin pharmaceutical benefit; and (d) have been appropriately managed for medication overuse headache by their medical practitioner prior to treatment with botulinum toxin pharmaceutical benefit. (2) A person mentioned in subsection (1) is not eligible to receive a botulinum toxin pharmaceuetical benefit under this Special Arrangement if the person does not achieve and maintain a 50% or greater reduction from baseline in the number of headache days per month after two treatment cycles (each of 12 weeks duration).